Nanoviricides owns a novel, multi-target, oral anti-viral platform now in clinical development. The successful completion of Phase 1 healthy participant dosing with no adverse events is a key milestone. There remains a need across many disease areas for effective antiviral therapies. The NV platform is very versatile and adaptable to different viral strains and types. Oral delivery is important for mass-market products.
Nanoviricides: Phase Ia/b healthy participant dosing completed; pox virus data
The NV-CoV-2 Phase I, Exhibit 1, has completed dosing of the 36 healthy participants in both single-dose (Phase 1a) and multiple-dose arms (Phase 1b). Participants received either a syrup or a gummy containing the anti-viral agent NV-387. T